4.29

0.94% 0.04

After Hours: 4.29

Onkure Therapeutics Inc (OKUR)

Overview News Price History Discussions Forecast

Onkure Therapeutics Inc stock is traded at $4.29, with a volume of 328.14K. It is up +0.94% in the last 24 hours and up +35.76% over the past month. OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Previous Close:

$4.25

Open:

$4.29

24h Volume:

328.14K

Relative Volume:

0.99

Market Cap:

$173.30M

Revenue:

Net Income/Loss:

$-58.75M

P/E Ratio:

-0.9914

EPS:

-4.327

Net Cash Flow:

$-50.79M

1W Performance:

+2.39%

1M Performance:

+35.76%

6M Performance:

+45.92%

1Y Performance:

+77.27%

1-Day Range:

$4.18

$4.50

1-Week Range:

$4.015

$4.545

52-Week Range:

$1.91

$5.38

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Name

Onkure Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(720) 307-2892

Address

6707 WINCHESTER CIRCLE, SUITE 400, BOULDER

Employee

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

OKUR's Discussions on Twitter

Compare OKUR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OKUR Onkure Therapeutics Inc	4.29	169.66M	0	-58.75M	-50.79M	-4.327
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-30-25	Initiated	Evercore ISI	Outperform
Dec-05-24	Initiated	Leerink Partners	Outperform
Oct-10-24	Initiated	Oppenheimer	Outperform
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-15-23	Downgrade	Jefferies	Buy → Hold
Dec-15-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-14-23	Downgrade	BofA Securities	Buy → Underperform
Dec-14-23	Downgrade	Ladenburg Thalmann	Buy → Neutral
Dec-14-23	Downgrade	Piper Sandler	Overweight → Neutral
Dec-14-23	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-15-23	Initiated	William Blair	Outperform
Aug-28-23	Initiated	H.C. Wainwright	Buy
Jul-03-23	Initiated	BofA Securities	Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Jan-27-22	Initiated	Robert W. Baird	Outperform
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-22-21	Initiated	Ladenburg Thalmann	Buy
May-04-21	Initiated	Jefferies	Buy
May-04-21	Initiated	Piper Sandler	Overweight
May-04-21	Initiated	SVB Leerink	Outperform

View All

Onkure Therapeutics Inc Stock (OKUR) Latest News

Jun 13, 2026

OKUR Q1 2026 Earnings: EPS Miss by 46.55% Signals Aggressive Pipeline InvestmentEarnings Revision Upgrade - newsline.com

Jun 13, 2026

Jun 10, 2026

OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 10, 2026

Jun 08, 2026

OnKure Therapeutics (OKUR) director receives 7,650 stock options grant - Stock Titan

Jun 08, 2026

OnKure Therapeutics (OKUR) director awarded 1,275 stock options at $4.30 strike - Stock Titan

Jun 08, 2026

OnKure (OKUR) director awarded 7,650 stock options at $4.30 strike - Stock Titan

Jun 08, 2026

Onkure Therapeutics patents new PI3Kα mutant inhibitors - BioWorld News

Jun 08, 2026

Jun 07, 2026

OKUR Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue StageSlow Growth Warning - newsline.com

Jun 07, 2026

Jun 05, 2026

OnKure Shareholders Approve Amended 2024 Equity Incentive Plan - The Globe and Mail

Jun 05, 2026

Jun 04, 2026

OnKure (NASDAQ: OKUR) holders back equity plan changes and board slate - Stock Titan

Jun 04, 2026

Jun 02, 2026

OnKure Therapeutics (OKUR) Holds Steady Near Support: Can $4.43 Resistance Be Breached?Breakout Confirmation - newsline.com

Jun 02, 2026

Jun 01, 2026

OKUR Q1 2026 Earnings: EPS Miss of 46.6% Highlights Early-Stage R&D CostsGuidance Upgrade Report - thelegaladvocate.com

Jun 01, 2026

May 29, 2026

OnKure Therapeutics (OKUR) Advances 2.55% as Stock Holds Above Key SupportBollinger Expansion - The Legal Advocate

May 29, 2026

May 28, 2026

OKUR Q1 2026 Earnings: Wider EPS Loss Underscores Heavy R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Surprise Stocks - newsline.com

May 28, 2026

May 27, 2026

[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan

May 27, 2026

OKUR Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEarnings Stability Report - The Legal Advocate

May 27, 2026

May 26, 2026